The Chinese calendar says 2013 is the year of the snake, but the market says it's the year of biotech. Major biotechnology ETFs and indices have walloped the broader market by more than 25% since the beginning of the year.
Acquisition No. 1: Onyx Pharmaceuticals In August, Amgen (NASDAQ: AMGN acquired Onyx Pharmaceuticals for $9.7 billion
Acquisition No. 2: Elan In July, Perrigo (NYSE: PRGO ) bought Elan for $8.6 billion.
Acquisition No. 3: Omthera In May, AstraZeneca (NYSE: AZN ) bought Omthera for $443 million.
That is good for those investors. for us . . . well well well, I think that at this moment MCET can be given away for free and no one will take it. 4 years of expecting the miracle. I am a stubborn hard headed investor.
if you didn't sell a few months ago on the miracle run you have nobody to blame but yourself. Look closely, there is nothing to be given away. I don't know who is buying this stuff, insiders certainly aren't. I think the smart ones buy at .0011 and sell at .0012.